Online citations, reference lists, and bibliographies.
← Back to Search

The Bioavailability Of Intranasal Salmon Calcitonin In Healthy Volunteers With And Without A Permeation Enhancer

W. Lee, R. D. Ennis, J. Longenecker, P. Bengtsson
Published 2004 · Chemistry, Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Serum levels of radioimmunoactive salmon calcitonin (sCT) were determined in 10 healthy volunteers after intranasal administration (IN) of 100-, 205-, and 450-IU of sCT with 0.5% sodium tauro-24,25-dihydrofusidate (STDHF), a 200-IU commercial IN formulation, and a 100-IU intramuscular (IM) formulation. Relative to the IM dose, the bioavailabilities of the IN formulations containing 0.5% STDHF were 3.9, 7.9, and 7.4%, respectively. The 200-IU commercial formulation resulted in serum levels above the limit of detection in only 5 of 10 patients, with an average bioavailability of 1.6%.
This paper references
10.1002/JPS.2600760709
Analysis of structural requirements for the absorption of drugs and macromolecules from the nasal cavity.
C. Mcmartin (1987)
10.1097/00003086-197709000-00010
Human calcitonin treatment of Paget's disease of bone.
F. Singer (1977)
10.1016/0026-0495(84)90187-2
Long-term calcitonin therapy in postmenopausal osteoporosis.
H. Gruber (1984)
10.1023/A:1015885204249
The Effect of Sodium Tauro-24,25-Dihydrofusidate on the Nasal Absorption of Human Growth Hormone in Three Animal Models
Patricia A. Baldwin (2004)
Assessment of the biological effectiveness of nasal synthetic salmon calcitonin (SSCT) by comparison with intramuscular (i.m.) or placebo injection in normal subjects.
J. Reginster (1987)
10.1007/978-1-4757-9960-6_19
Intranasal Delivery of the Peptide, Salmon Calcitonin
M. Hanson (1986)
10.1016/0378-5173(86)90137-7
Aminopeptidase activity in homogenates of various absorptive mucosae m the albino rabbit: implications in peptide delivery
R. Stratford (1986)
10.1056/NEJM198101293040505
Calcitonin: physiology and pathophysiology.
L. Austin (1981)
10.1055/S-2007-1004876
Biological activity of nasally administered insulin in normal subjects.
M. Nolte (1990)
10.7326/0003-4819-107-6-923
Salmon calcitonin in the treatment of postmenopausal osteoporosis.
V. Fatourechi (1987)
10.1016/0002-9343(74)90815-8
Response of Paget's disease to porcine and salmon calcitonins: effects of long-term treatment.
J. Derose (1974)
10.1111/j.1365-2265.1989.tb00443.x
NASAL CALCITONIN FOR TREATMENT OF ESTABLISHED OSTEOPOROSIS
K. Overgaard (1989)
Side effects of synthetic salmon calcitonin given by intranasal spray compared with intramuscular injection.
J. Reginster (1985)



This paper is referenced by
10.5530/RJPS.2012.1.4
Nasal drug delivery–a review
Twarita Deshpande (2012)
RECENT TECHNIQUES IN NASAL DRUG DELIVERY: A REVIEW
Parmar Harshad (2010)
10.4062/biomolther.2013.010
Zanamivir Oral Delivery: Enhanced Plasma and Lung Bioavailability in Rats
S. K. S. Shanmugam (2013)
10.1016/S0378-5173(03)00090-5
Enhancing effect of chitosan on nasal absorption of salmon calcitonin in rats: comparison with hydroxypropyl- and dimethyl-beta-cyclodextrins.
Prapasri Sinswat (2003)
10.1517/17425247.2011.566265
Non-invasive iontophoretic delivery of peptides and proteins across the skin
T. Gratieri (2011)
10.1211/0022357056073
Effect of chitosan on the intranasal absorption of salmon calcitonin in sheep
M. Hinchcliffe (2005)
10.1007/s00223-002-0034-9
Intranasal Delivery of PEGylated Salmon Calcitonins: Hypocalcemic Effects in Rats
K. C. Lee (2002)
10.3329/ICPJ.V1I11.12065
Solid Lipid Nanoparticles (SLN): Method, Characterization and Applications
A. Garud (2012)
A DESCRIPTIVE REVIEW ON VARIOUS LIPIDS AND TECHNIQUES USED IN FORMULATION OF SOLID LIPID NANOPARTICLES
Sukhwinder Singh (2016)
10.3109/03639045.2012.684388
Transdermal absorption and stability enhancement of salmon calcitonin by Tat peptide
J. Manosroi (2013)
10.1023/A:1016026711364
Temperature and pH-sensitive Polymers for Human Calcitonin Delivery
A. Serres (2004)
10.1023/A:1016051600828
Enhancement of Nasal Salmon Calcitonin Absorption by Lauroylcarnitine Chloride in Rats
S. Kagatani (2004)
Analytical techniques and formulation strategies for the therapeutic protein alkaline phosphatase
H. Eriksson (2004)
Solid Lipid Nanoparticles: The Frontier in Drug Delivery.
R. Ali (2014)
10.2165/00024677-200403020-00006
Calcitonin Therapy in Osteoporosis
M. Muñoz-Torres (2004)
10.1002/9781118660485.CH16
ADVANCED DRUG DELIVERY
R. Ho (2004)
10.1016/j.nano.2020.102153
Bone targeted delivery of Salmon calcitonin hydroxyapatite nanoparticles for sublingual osteoporosis therapy (SLOT).
Darsheen J. Kotak (2020)
10.1023/B:PHAR.0000026823.82950.ff
Nasal route and drug delivery systems
S. Türker (2004)
10.1016/S1773-2247(06)50061-9
Chitosan nanocapsules: a new carrier for nasal peptide delivery
C. Prego (2006)
10.1007/978-1-4020-6289-6_6
Alternative Applications for Drug Delivery: Nasal and Pulmonary Routes
A. Ozer (2007)
10.1016/J.JCONREL.2007.04.006
Influence of fillers in powder formulations containing N-acetyl-L-cysteine on nasal peptide absorption.
T. Matsuyama (2007)
10.1201/B10846-10
Transmucosal and Ocular Drug Delivery
Vasant V. Ranade (2011)
The potential of electronic cigarette technology to deliver small molecular weight drugs to the central nervous system
Montserrat Castillo Carrizales (2019)
10.1201/B12778-8
Nasal and Pulmonary Delivery of Macromolecules to Treat Respiratory and Nonrespiratory Diseases
D. Paturi (2012)
10.1517/17425247.5.4.371
Advances in PEGylation of important biotech molecules: delivery aspects
S. Ryan (2008)
Lipid Nanoparticles : Future of Oral Drug Delivery and their Current Trends and Regulatory Issues
Kriti Soni (2016)
10.1177/1932296814557518
Intranasal Glucagon
A. Pontiroli (2015)
10.3390/molecules14093754
Nasal Delivery of High Molecular Weight Drugs
Y. Ozsoy (2009)
10.1007/978-1-4020-6289-6
Nanomaterials and nanosystems for biomedical applications
M. R. Mozafari (2007)
10.4155/tde.15.23
The use of solid lipid nanoparticles for sustained drug release.
A. Attama (2015)
10.1002/9781118794203.CH03
Drug delivery across the nasal mucosa
M. Armstrong (2014)
10.1002/JPS.10537
Stability of PEGylated salmon calcitonin in nasal mucosa.
D. Na (2004)
See more
Semantic Scholar Logo Some data provided by SemanticScholar